Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07610590 · ClinicalTrials.gov registry record
guideSEQ: Genomic Understanding, Impact, Decision & Ethics in Prenatal Sequencing
A clinical trial, sponsored by Columbia University.
- Recruiting
- Registry status
- 1,042
- Enrollment target
NCT07610590: Recruiting study, sponsored by Columbia University.
NCT07610590 is a clinical trial that is actively recruiting participants, run by Columbia University. The registered enrollment target is 1,042 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07610590 is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- 1,042 participants
- Enrollment target
Study Summary
This study looks at whether genome sequencing should be used more routinely during pregnancy, even when ultrasounds look normal. Genome sequencing can examine nearly all of a baby's genes and may find genetic conditions that standard tests do not detect. Researchers will compare this test with current prenatal testing to see if it provides helpful information for families and doctors. The study will also explore how parents decide what kinds of genetic information they want to receive and how this information affects their experience during pregnancy. The goal is to understand whether genome sequencing can be used in a way that is helpful, responsible, and supportive for families in the future.
Primary Outcome
The incremental frequency of fetal genetic conditions identified and reported by genomic sequencing (GS) compared to those found by standard-of-care (SOC) testing, including pathogenic, likely pathogenic, or variant of uncertain significance (VUS) variants identified by sequencing and deemed reportable by the Variant Adjudication Committee
Interventions
- GENETIC Genome Sequencing (GS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,042 participants |
| Start Date | 2026-04-29 |
| Est. Completion | 2029-07-31 |
What NCT07610590 shows while recruiting
NCT07610590 is an observational study that tracks outcomes without assigning an intervention. Its 1,042 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Genome Sequencing (GS) is the first listed.
NCT07610590 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07610590 about?
NCT07610590 is a clinical study titled "guideSEQ: Genomic Understanding, Impact, Decision & Ethics in Prenatal Sequencing". This study looks at whether genome sequencing should be used more routinely during pregnancy, even when ultrasounds look normal. Genome sequencing can examine nearly all of a baby's genes and may find genetic conditions that standard tests do not detect. Researchers will compare this test with curre...
What is the current status of trial NCT07610590?
This trial is currently recruiting. The enrollment target is 1,042 participants. The study started on 2026-04-29. Estimated completion is 2029-07-31.
What interventions are being tested in trial NCT07610590?
The interventions under investigation include: Genome Sequencing (GS) (GENETIC).
Who is sponsoring clinical trial NCT07610590?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04685616 · 1,042 participants · Phase 3
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
- NCT05219110 · 1,040 participants · NA
Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection
- NCT06564948 · 1,040 participants · NA
Treatment for Individuals Interacting with the Criminal Justice System
- NCT06661720 · 1,040 participants · Phase 3
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI